BRAT1 mutations present with a spectrum of clinical severity

Siddharth Srivastava, Heather E. Olson, Julie S. Cohen, Cynthia S. Gubbels, Sharyn Lincoln, Brigette Tippin Davis, Layla Shahmirzadi, Siddharth Gupta, Jonathan Picker, Timothy W. Yu, David T. Miller, Janet S. Soul, Andrea Poretti, Sakkubai Naidu

Research output: Contribution to journalArticle

Abstract

Mutations in BRAT1, encoding BRCA1-associated ATM activator 1, are associated with a severe phenotype known as rigidity and multifocal seizure syndrome, lethal neonatal (RMFSL; OMIM # 614498), characterized by intractable seizures, hypertonia, autonomic instability, and early death. We expand the phenotypic spectrum of BRAT1 related disorders by reporting on four individuals with various BRAT1 mutations resulting in clinical severity that is either mild or moderate compared to the severe phenotype seen in RMFSL. Representing mild severity are three individuals (Patients 1-3), who are girls (including two sisters, Patients 1-2) between 4 and 10 years old, with subtle dysmorphisms, intellectual disability, ataxia or dyspraxia, and cerebellar atrophy on brain MRI; additionally, Patient 3 has well-controlled epilepsy and microcephaly. Representing moderate severity is a 15-month-old boy (Patient 4) with severe global developmental delay, refractory epilepsy, microcephaly, spasticity, hyperkinetic movements, dysautonomia, and chronic lung disease. In contrast to RMFSL, his seizure onset occurred later at 4 months of age, and he is still alive. All four of the individuals have compound heterozygous BRAT1 mutations discovered via whole exome sequencing: c.638dupA (p.Val214Glyfs*189); c.803+1G>C (splice site mutation) in Patients 1-2; c.638dupA (p.Val214Glyfs*189); c.419T>C (p.Leu140Pro) in Patient 3; and c.171delG (p.Glu57Aspfs*7); c.419T>C (p.Leu140Pro) in Patient 4. Only the c.638dupA (p.Val214Glyfs*189) mutation has been previously reported in association with RMFSL. These patients illustrate that, compared with RMFSL, BRAT1 mutations can result in both moderately severe presentations evident by later-onset epilepsy and survival past infancy, as well as milder presentations that include intellectual disability, ataxia/dyspraxia, and cerebellar atrophy.

Original languageEnglish (US)
JournalAmerican Journal of Medical Genetics, Part A
DOIs
StateAccepted/In press - 2016

Fingerprint

Mutation
Epilepsy
Seizures
Apraxias
Microcephaly
Intellectual Disability
Atrophy
Phenotype
Primary Dysautonomias
Hyperkinesis
Exome
Genetic Databases
Cerebellar Ataxia
Ataxia
Lung Diseases
Siblings
Chronic Disease
Brain

Keywords

  • BRAT1
  • Cerebellar atrophy
  • Clinical severity
  • Epilepsy
  • Intellectual disability
  • RMFSL

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Srivastava, S., Olson, H. E., Cohen, J. S., Gubbels, C. S., Lincoln, S., Davis, B. T., ... Naidu, S. (2016). BRAT1 mutations present with a spectrum of clinical severity. American Journal of Medical Genetics, Part A. DOI: 10.1002/ajmg.a.37783

BRAT1 mutations present with a spectrum of clinical severity. / Srivastava, Siddharth; Olson, Heather E.; Cohen, Julie S.; Gubbels, Cynthia S.; Lincoln, Sharyn; Davis, Brigette Tippin; Shahmirzadi, Layla; Gupta, Siddharth; Picker, Jonathan; Yu, Timothy W.; Miller, David T.; Soul, Janet S.; Poretti, Andrea; Naidu, Sakkubai.

In: American Journal of Medical Genetics, Part A, 2016.

Research output: Contribution to journalArticle

Srivastava, S, Olson, HE, Cohen, JS, Gubbels, CS, Lincoln, S, Davis, BT, Shahmirzadi, L, Gupta, S, Picker, J, Yu, TW, Miller, DT, Soul, JS, Poretti, A & Naidu, S 2016, 'BRAT1 mutations present with a spectrum of clinical severity' American Journal of Medical Genetics, Part A. DOI: 10.1002/ajmg.a.37783
Srivastava S, Olson HE, Cohen JS, Gubbels CS, Lincoln S, Davis BT et al. BRAT1 mutations present with a spectrum of clinical severity. American Journal of Medical Genetics, Part A. 2016. Available from, DOI: 10.1002/ajmg.a.37783

Srivastava, Siddharth; Olson, Heather E.; Cohen, Julie S.; Gubbels, Cynthia S.; Lincoln, Sharyn; Davis, Brigette Tippin; Shahmirzadi, Layla; Gupta, Siddharth; Picker, Jonathan; Yu, Timothy W.; Miller, David T.; Soul, Janet S.; Poretti, Andrea; Naidu, Sakkubai / BRAT1 mutations present with a spectrum of clinical severity.

In: American Journal of Medical Genetics, Part A, 2016.

Research output: Contribution to journalArticle

@article{7477c3e22afd4bf0955b6c2a0ea9926d,
title = "BRAT1 mutations present with a spectrum of clinical severity",
abstract = "Mutations in BRAT1, encoding BRCA1-associated ATM activator 1, are associated with a severe phenotype known as rigidity and multifocal seizure syndrome, lethal neonatal (RMFSL; OMIM # 614498), characterized by intractable seizures, hypertonia, autonomic instability, and early death. We expand the phenotypic spectrum of BRAT1 related disorders by reporting on four individuals with various BRAT1 mutations resulting in clinical severity that is either mild or moderate compared to the severe phenotype seen in RMFSL. Representing mild severity are three individuals (Patients 1-3), who are girls (including two sisters, Patients 1-2) between 4 and 10 years old, with subtle dysmorphisms, intellectual disability, ataxia or dyspraxia, and cerebellar atrophy on brain MRI; additionally, Patient 3 has well-controlled epilepsy and microcephaly. Representing moderate severity is a 15-month-old boy (Patient 4) with severe global developmental delay, refractory epilepsy, microcephaly, spasticity, hyperkinetic movements, dysautonomia, and chronic lung disease. In contrast to RMFSL, his seizure onset occurred later at 4 months of age, and he is still alive. All four of the individuals have compound heterozygous BRAT1 mutations discovered via whole exome sequencing: c.638dupA (p.Val214Glyfs*189); c.803+1G>C (splice site mutation) in Patients 1-2; c.638dupA (p.Val214Glyfs*189); c.419T>C (p.Leu140Pro) in Patient 3; and c.171delG (p.Glu57Aspfs*7); c.419T>C (p.Leu140Pro) in Patient 4. Only the c.638dupA (p.Val214Glyfs*189) mutation has been previously reported in association with RMFSL. These patients illustrate that, compared with RMFSL, BRAT1 mutations can result in both moderately severe presentations evident by later-onset epilepsy and survival past infancy, as well as milder presentations that include intellectual disability, ataxia/dyspraxia, and cerebellar atrophy.",
keywords = "BRAT1, Cerebellar atrophy, Clinical severity, Epilepsy, Intellectual disability, RMFSL",
author = "Siddharth Srivastava and Olson, {Heather E.} and Cohen, {Julie S.} and Gubbels, {Cynthia S.} and Sharyn Lincoln and Davis, {Brigette Tippin} and Layla Shahmirzadi and Siddharth Gupta and Jonathan Picker and Yu, {Timothy W.} and Miller, {David T.} and Soul, {Janet S.} and Andrea Poretti and Sakkubai Naidu",
year = "2016",
doi = "10.1002/ajmg.a.37783",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - BRAT1 mutations present with a spectrum of clinical severity

AU - Srivastava,Siddharth

AU - Olson,Heather E.

AU - Cohen,Julie S.

AU - Gubbels,Cynthia S.

AU - Lincoln,Sharyn

AU - Davis,Brigette Tippin

AU - Shahmirzadi,Layla

AU - Gupta,Siddharth

AU - Picker,Jonathan

AU - Yu,Timothy W.

AU - Miller,David T.

AU - Soul,Janet S.

AU - Poretti,Andrea

AU - Naidu,Sakkubai

PY - 2016

Y1 - 2016

N2 - Mutations in BRAT1, encoding BRCA1-associated ATM activator 1, are associated with a severe phenotype known as rigidity and multifocal seizure syndrome, lethal neonatal (RMFSL; OMIM # 614498), characterized by intractable seizures, hypertonia, autonomic instability, and early death. We expand the phenotypic spectrum of BRAT1 related disorders by reporting on four individuals with various BRAT1 mutations resulting in clinical severity that is either mild or moderate compared to the severe phenotype seen in RMFSL. Representing mild severity are three individuals (Patients 1-3), who are girls (including two sisters, Patients 1-2) between 4 and 10 years old, with subtle dysmorphisms, intellectual disability, ataxia or dyspraxia, and cerebellar atrophy on brain MRI; additionally, Patient 3 has well-controlled epilepsy and microcephaly. Representing moderate severity is a 15-month-old boy (Patient 4) with severe global developmental delay, refractory epilepsy, microcephaly, spasticity, hyperkinetic movements, dysautonomia, and chronic lung disease. In contrast to RMFSL, his seizure onset occurred later at 4 months of age, and he is still alive. All four of the individuals have compound heterozygous BRAT1 mutations discovered via whole exome sequencing: c.638dupA (p.Val214Glyfs*189); c.803+1G>C (splice site mutation) in Patients 1-2; c.638dupA (p.Val214Glyfs*189); c.419T>C (p.Leu140Pro) in Patient 3; and c.171delG (p.Glu57Aspfs*7); c.419T>C (p.Leu140Pro) in Patient 4. Only the c.638dupA (p.Val214Glyfs*189) mutation has been previously reported in association with RMFSL. These patients illustrate that, compared with RMFSL, BRAT1 mutations can result in both moderately severe presentations evident by later-onset epilepsy and survival past infancy, as well as milder presentations that include intellectual disability, ataxia/dyspraxia, and cerebellar atrophy.

AB - Mutations in BRAT1, encoding BRCA1-associated ATM activator 1, are associated with a severe phenotype known as rigidity and multifocal seizure syndrome, lethal neonatal (RMFSL; OMIM # 614498), characterized by intractable seizures, hypertonia, autonomic instability, and early death. We expand the phenotypic spectrum of BRAT1 related disorders by reporting on four individuals with various BRAT1 mutations resulting in clinical severity that is either mild or moderate compared to the severe phenotype seen in RMFSL. Representing mild severity are three individuals (Patients 1-3), who are girls (including two sisters, Patients 1-2) between 4 and 10 years old, with subtle dysmorphisms, intellectual disability, ataxia or dyspraxia, and cerebellar atrophy on brain MRI; additionally, Patient 3 has well-controlled epilepsy and microcephaly. Representing moderate severity is a 15-month-old boy (Patient 4) with severe global developmental delay, refractory epilepsy, microcephaly, spasticity, hyperkinetic movements, dysautonomia, and chronic lung disease. In contrast to RMFSL, his seizure onset occurred later at 4 months of age, and he is still alive. All four of the individuals have compound heterozygous BRAT1 mutations discovered via whole exome sequencing: c.638dupA (p.Val214Glyfs*189); c.803+1G>C (splice site mutation) in Patients 1-2; c.638dupA (p.Val214Glyfs*189); c.419T>C (p.Leu140Pro) in Patient 3; and c.171delG (p.Glu57Aspfs*7); c.419T>C (p.Leu140Pro) in Patient 4. Only the c.638dupA (p.Val214Glyfs*189) mutation has been previously reported in association with RMFSL. These patients illustrate that, compared with RMFSL, BRAT1 mutations can result in both moderately severe presentations evident by later-onset epilepsy and survival past infancy, as well as milder presentations that include intellectual disability, ataxia/dyspraxia, and cerebellar atrophy.

KW - BRAT1

KW - Cerebellar atrophy

KW - Clinical severity

KW - Epilepsy

KW - Intellectual disability

KW - RMFSL

UR - http://www.scopus.com/inward/record.url?scp=84977484705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977484705&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.37783

DO - 10.1002/ajmg.a.37783

M3 - Article

JO - American Journal of Medical Genetics, Part A

T2 - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

ER -